psalexa

Age-Related Macular Degeneration Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • Published: May 2017
  • Report Code: LS11020
  • Available Format: PDF
  • Pages: 143

Note: This report can also be updated as of date and delivered within 1-2 working days of purchase confirmation

Disease Overview

Age-related macular degeneration is a disorder that causes loss of vision in a person due to macula damage; macula is that part of an eye, which helps a person to see, it is made up of millions of light-sensing cells which provide sharp and central vision. Age-related macular degeneration progresses slowly in an individual and can eventually lead to blindness. The most common symptom of Age-related macular degeneration is blurry vision. Age-related macular degeneration is common in people who are above the age of 50 years and is of two types namely, Dry Age-related macular degeneration and Wet Age-related macular degeneration. Dry Age-related macular degeneration is the most common form and almost eight out of ten Age-related macular degeneration patients suffer from this type of macular degeneration. Wet Age-related macular degeneration is less common, but is a more serious condition as compared to Dry Age-related macular degeneration. Various companies are developing drugs with promising targets for the treatment of the disease. Targeted therapy is more efficient in achieving good results. The potential targets are expected to possibly stop or slow down the progress of the disease with better efficacy and less side effects. The continuous efforts by various companies to find better and new treatment strategies with potential targets such as mitogen-activated protein kinase, complement factor D, retinal pigment epithelium cell, signal transducer and activator of transcription 3 (STAT3), also prove to be effective in treating Age-related macular degeneration.

Pipeline Analysis

As of May 2017, the Age-related macular degeneration pipeline comprises of approximately 55 drug candidates in different stages of development.

 

NUMBER OF AGE-RELATED MACULAR DEGENERATION THERAPEUTICS UNDER DEVELOPMENT(2017)

Age-Related Macular Degeneration Therapeutics Pipeline Analysis

 

Competitive Landscape

Some of the key players developing drugs for the treatment of Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche and others.

Scope for Customization

P&S Intelligence offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles
Place An Order
USD 2200 USD 2600 USD 3950
Customized Report Solution

Get a bespoke market intelligence solution

 
We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need Us

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws